TL;DR
Food Safety News publisher Bill Marler says he is asking the FDA to adopt two citizen petitions focused on company and location disclosures in food outbreak investigations. His argument is that the agency’s own commitments to transparency in food safety support fuller public reporting, but the supplied source text ends before describing the petitions’ full requests or the FDA’s response.
Food Safety News publisher Bill Marler says he is asking the FDA to make more information public in food outbreak investigations, arguing that two citizen petitions align with the agency’s stated commitment to “radical transparency.” The editorial points to company names and outbreak locations as information missing from some FDA summaries, but the supplied article excerpt cuts off before setting out the petitions’ complete requests or the agency’s current position.
Marler’s editorial says the petitions ask for steps the federal government has previously taken, publicly supported or, as of October 26, 2026, had not been told by the Department of Justice it lacked authority to take. That is Marler’s characterization of the petitions and the legal status; the provided material does not include the petitions themselves or supporting DOJ correspondence.
The editorial argues that FDA outbreak summaries have provided useful information but can omit details that help the public identify the implicated company and where an outbreak occurred, a concern also raised in coverage of the Food Traceability Rule. It cites reporting on a mango outbreak summary that did not name a company and a fatal Listeria investigation summary in which key details, including patients’ states, were redacted. It also says FDA did not identify a grower, processor or brand when it closed a September romaine E. coli investigation, an issue echoed in reporting on an E. coli outbreak.
Marler further describes a 50-person E. coli O157:H7 outbreak linked to chicken wraps, part of the broader transparency concerns discussed in a related account of food safety petitions. He says the public learned the brand through a lawsuit and newspaper reporting, rather than an FDA or USDA Food Safety and Inspection Service announcement, and notes that FSIS later confirmed the source to a reporter. Marler discloses that he represents plaintiffs in that outbreak. The excerpt ends during his account of FDA’s October 28 notice closing the investigation, so it does not provide the rest of his description.
What Missing Names Mean in Outbreaks
Company and location disclosures can help consumers determine whether a product they bought may be connected to an outbreak and help public health officials communicate risks. Marler’s argument is that a summary that records an investigation but withholds identifying details may leave the public unable to act on the information.
The issue also concerns accountability and the balance between public health disclosure and protections for confidential business information. The editorial says FDA previously invoked the Trade Secrets Act when responding to a petition from Stop Foodborne Illness about company names. Marler argues that the agency now has a basis to disclose them, but the excerpt does not establish that FDA has accepted this interpretation or changed its disclosure policy.
How FDA Adopted Transparency Language
The editorial traces the phrase “radical transparency” from HHS Secretary Robert F. Kennedy Jr.’s 2025 pledge to FDA food-safety communications. It says HHS connected the phrase to food in a March 10, 2025, announcement about examining the self-affirmed GRAS pathway, and that FDA later used it in a July letter to food industry leaders about recall communications.
On September 24, 2025, FDA’s food program introduced Executive Incident Summary abstracts for closed outbreak investigations. Marler credits those summaries as a step forward while arguing that identifying details remain missing. The editorial says FDA’s food program was then led by Kyle Diamantas, who later became acting FDA commissioner; it also reports that former commissioner Marty Makary resigned in May 2026 and that President Donald Trump nominated Heidi Overton in August. These developments provide the leadership context for Marler’s appeal, not confirmation of any petition outcome.
“At the FDA, we believe that radical transparency in food safety and nutrition actions is key to reducing foodborne illness and chronic disease.”
— FDA, quoted in its July 9, 2025, letter to food industry leaders, according to the editorial
Petition Requests and FDA Response
The source material provided here is incomplete: it ends mid-sentence in the account of the chicken-wrap outbreak. It does not give the full text or filing dates of both petitions, identify every disclosure change requested, or include a response from FDA. The editorial’s assertion about DOJ and the agency’s legal authority is also not independently documented in the supplied excerpt.
It is consequently unclear whether FDA has accepted, rejected or begun reviewing the petitions, whether it plans to revise its outbreak summaries, or how it would address any legal or commercial-confidentiality concerns. No response from FDA, HHS, DOJ or the named companies is included in the material.
FDA Review and Disclosure Decisions
The next developments to watch are the complete petition texts and any formal FDA response. The agency could explain whether it considers company names and location details confidential, clarify what information it can release under existing law, or change how it publishes summaries of closed investigations.
Until those records or a response are available, the confirmed development is Marler’s public appeal and his account of two petitions—not a decision by FDA to disclose additional information. Readers seeking to evaluate the requests will need the full filings and the agency’s position.
Key Questions
What is Bill Marler asking the FDA to do?
Marler says two citizen petitions seek greater disclosure in food outbreak reporting, particularly information about companies and locations. The supplied excerpt does not include the petitions’ complete wording.
Has the FDA agreed to the requests?
The provided material does not report an FDA decision or response. It establishes that Marler is making the request, not that the agency has changed its policy.
Why does Marler say company names matter?
He argues that identifying details can help consumers understand whether products may be involved and can make outbreak summaries more useful. That is the editorial’s case for disclosure, not a reported FDA finding.
What information is still missing?
The full petition texts, their filing details, the complete account of the chicken-wrap investigation and any formal FDA response are not included in the supplied source material.
Source: foodsafetynews.com
